ArticleActa ophthalmologica2026
Neovascular age-related macular degeneration without drusen.
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo describe the clinical characteristics and 1-year follow-up of patients with neovascular AMD (nAMD) without drusen in either eye.
methodsThis is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence of drusen or signs of another underlying disease in either eye. The medical charts and multimodal imaging (MMI) were evaluated by two independent graders. Eyes were divided into two groups: polypoidal choroidal vasculopathy (PCV)-associated macular neovascularization (MNV) and non-PCV MNV. We evaluated the visual acuity (VA) at baseline and 1 year after baseline; complete resolution of macular fluid on optical coherence tomography (OCT) during 1 year of follow-up; required treatments to achieve a complete resolution of macular fluid on OCT; complication rate.
resultsWe included 106 eyes of 99 patients, with a median age of 73 years. Seventy-one eyes had PCV-associated MNV, and 35 eyes had non-PCV MNV. The overall median baseline VA was 0.22 logMAR (Snellen 20/30), and 0.15 logMAR (Snellen 20/28) at 1 year follow-up. Subretinal haemorrhage was more common in PCV-associated MNV compared to non-PCV MNV, both at initial presentation (21% vs. 17%) and during the 1 year follow-up period (23% vs. 11%). In total, 31 out of 48 eyes (65%) achieved complete resolution of macular fluid on OCT during follow-up, most commonly achieved with combined photodynamic therapy (PDT) + intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
conclusionnAMD can occur without the presence of drusen in either eye. Treatment with anti-VEGF injections, PDT or a combination thereof appears to be effective, but more research is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.